Clinical Trial Update: A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of ulocuplumab and ibrutinib in patients with mutated CXCR4 Waldenström's macroglobulinemia was terminated; results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Ulocuplumab (ulocuplumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 1 | Status: TERMINATED | Results posted: 2024-05-03